PharmaShots Weekly Snapshots (May 06 – May 10, 2024)
This week PharmaShots’ news was all about the updates on M&A, Pharma, Clinical Trials, Regulatory & MedTech. Check out our full report below:
Johnson & Johnson Highlights Data from the P-I Study of TAR-210 for Non-Muscle-Invasive Bladder Cancer (NMIBC) at AUA 2024
Read More: Johnson & Johnson
UroGen Pharma Reports Real-World Analysis of Jelmyto for Upper Tract Urothelial Carcinoma
Read More: UroGen Pharma
EyePoint Pharmaceuticals Reports the P-II (PAVIA) Study Data of Duravyu for Non-Proliferative Diabetic Retinopathy
Read More: EyePoint Pharmaceuticals
Edgewise Therapeutics Reports First Patient Dosing in P-II Study of EDG-7500 to Treat Obstructive Hypertrophic Cardiomyopathy
Read More: Edgewise Therapeutics
VYNE Therapeutics Reports the US FDA’s Acceptance of IND for VYN202 to Treat Autoimmune Diseases
Read More: VYNE Therapeutics
Modalis Therapeutics Unveils Epigenome Editing Therapy MDL-101 for Treatment of LAMA2-Deficient CMD
Read More: Modalis Therapeutics
Regeneron Reports Results from the P-I/II (CHORD) Study of DB-OTO for Hearing Loss
Read More: Regeneron
Acumen Pharmaceuticals Reports First Patient Dosing with Sabirnetug in P-II (ALTITUDE-AD) Study for Early Alzheimer’s Disease
Read More: Acumen Pharmaceuticals
Innovent Biologics Reports the P-III Trial Results of Mazdutide for Treating Type 2 Diabetes
Read More: Innovent Biologics
Merck Reports Results from the P-III (KEYNOTE-B21) Study of Keytruda Plus Chemotherapy for Endometrial Cancer
Read More: Merck
Fusion Pharmaceuticals Doses First Patient with FPI-2265 in P-II Study for Metastatic Castration-Resistant Prostate Cancer
Read More: Fusion Pharmaceuticals
IRLAB Therapeutics Gains the Swedish Medical Products Agency’s Approval to Initiate P-I Trial of IRL757 for Apathy
Read More: IRLAB Therapeutics
BMS Reports the US FDA’s Acceptance of BLA for Opdivo to Treat Clear Cell Renal Cell Carcinoma
Read More: BMS
Innovent’s IBI343 a Monotherapy Receives the NMPA’s Breakthrough Therapy Designation for Advanced Gastric Cancer (GC)
Read More: Innovent
Biotheryx Receives the US FDA’s IND Approval of BTX-9341 for Treating Breast Cancer
Read More: Biotheryx
SN Bioscience’s SNB-101 Gains the US FDA’s Fast Track Designation for Small Cell Lung Cancer
Read More: SN Bioscience
BioVersys Extends its Strategic Collaboration with GSK and Series C Round by CHF 12.3M
Read More: BioVersys
IRLAB and McQuade Center for Strategic Research and Development (MSRD) Collaborate to Develop IRL757 for Apathy
Read More: IRLAB & McQuade Center
ARTBIO Partners with Nucleus RadioPharma to Manufacture Pb-212 Radiolabeled Therapeutic Products
Read More: ARTBIO & Nucleus RadioPharma
Flagship Pioneering and Metaphore Biotechnologies Partner with Novo Nordisk to Develop Therapies for Obesity
Read More: Flagship Pioneering, Metaphore Biotechnologies & Novo Nordisk
Shionogi Partners with Maze Therapeutics for MZE001’s Rights to Treat Pompe Disease
Read More: Shionogi & Maze Therapeutics
Xbrane Biopharma and STADA Team Up with Valorum Biologics for Commercializing Xlucane (Biosimilar, Ranibizumab) Across the US
Read More: Xbrane Biopharma & STADA
Sanofi Partners with Novavax to Co-commercialize COVID-19 Vaccine and Develop Flu-COVID-19 Combination Vaccines
Read More: Sanofi & Novavax
US Medical Innovations Reports the US FDA’s Clearance of Canady Helios Cold Plasma Ablation System for Soft Tissue Ablation
Read More: US Medical Innovations
Catalent's Acquisition by Novo Holdings Put on Hold for 30 Days for Antitrust Review
Read More: Catalent & Novo
Arbor Biotechnologies to Acquire Serendipity Biosciences
Read More: Arbor Biotechnologies & Serendipity Biosciences
epiq Animal Health and KeraVet Bio Collaborate to Market KeraVet Gel for Wound Healing in Animals
Read More: epiq Animal Health & KeraVet Bio
Mozart Therapeutics Highlights Pre-clinical Data of KIR x ICOS CD8 Treg Modulator at Immunology 2024
Read More: Mozart Therapeutics
Seragon Biosciences Concludes SRN-901’s Pre-Clinical Study to Evaluate its Effect on Aging
Read More: Seragon Biosciences
The US FDA Grants Clearance to Indica Labs’ HALO AP Dx Digital Pathology Platform
Read More: Indica Labs
Related Post:- PharmaShots Weekly Snapshots (April 29 – May 03, 2024)
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.